U.S. INFLUENZA VACCINES MARKET ANALYSIS

Market Challenges And Opportunities

U.S. Influenza Vaccines Market - Driver

Increasing inorganic strategies such as product approval from regulatory authorities such as the U.S. Food and Drug Administration is expected to boost the growth of the U.S. influenza vaccines market. For instance, in February 2021, Seqirus USA Inc., a pharmaceutical company, announced that they had received approval from the U.S. Food and Drug Administration for Fluad Quadrivalent, the first adjuvanted quadrivalent influenza vaccine adults 65 years and older against. This vaccine will strengthen and broaden the body’s immune response against the influenza.

• Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration